$RPHM
Reneo Pharmaceuticals Inc

2022 Q2 Form 10-Q Financial Statement

#000155837022008103 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.299M $3.737M $3.524M
YoY Change 45.78% 114.52% 211.86%
% of Gross Profit
Research & Development $8.132M $9.278M $7.100M
YoY Change 29.51% 69.55% 38.67%
% of Gross Profit
Depreciation & Amortization $22.00K $19.00K $17.00K
YoY Change 120.0% 90.0% 70.0%
% of Gross Profit
Operating Expenses $12.43M $13.02M $10.62M
YoY Change 34.71% 80.41% 69.98%
Operating Profit -$12.43M -$13.02M
YoY Change 34.71% 80.41%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $119.0K -$21.00K $17.00K
YoY Change 891.67% -1150.0%
Pretax Income -$12.31M -$13.04M -$10.61M
YoY Change 33.59% 80.75% 69.71%
Income Tax
% Of Pretax Income
Net Earnings -$12.31M -$13.04M -$10.61M
YoY Change 33.59% 80.75% 69.71%
Net Earnings / Revenue
Basic Earnings Per Share -$0.50 -$0.53
Diluted Earnings Per Share -$503.3K -$0.53 -$433.0K
COMMON SHARES
Basic Shares Outstanding 24.46M 24.46M 24.42M
Diluted Shares Outstanding 24.46M 24.46M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $126.9M $138.7M $147.7M
YoY Change -24.19% 52.01%
Cash & Equivalents $118.3M $121.1M $124.7M
Short-Term Investments $8.588M $17.57M $23.01M
Other Short-Term Assets $5.159M $4.053M $6.064M
YoY Change 35.41% 73.28%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $132.0M $142.7M $153.7M
YoY Change -22.86% 52.54% 179.39%
LONG-TERM ASSETS
Property, Plant & Equipment $1.519M $237.0K $212.0K
YoY Change 1687.06% 192.59% 207.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $78.00K $78.00K $78.00K
YoY Change 0.0% -95.36% -38.58%
Total Long-Term Assets $1.597M $1.697M $290.0K
YoY Change 879.75% -3.63% 47.96%
TOTAL ASSETS
Total Short-Term Assets $132.0M $142.7M $153.7M
Total Long-Term Assets $1.597M $1.697M $290.0K
Total Assets $133.6M $144.4M $154.0M
YoY Change -22.01% 51.5% 178.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.560M $1.566M $2.022M
YoY Change 259.45% 181.65% 122.69%
Accrued Expenses $6.775M $5.887M $4.180M
YoY Change 133.46% 74.48% 13.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.335M $7.910M $6.202M
YoY Change 149.85% 101.27% 35.41%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.116M $1.184M $167.0K
YoY Change 167.63% 3600.0%
Total Long-Term Liabilities $1.116M $1.184M $167.0K
YoY Change 167.63% 3600.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.335M $7.910M $6.202M
Total Long-Term Liabilities $1.116M $1.184M $167.0K
Total Liabilities $9.451M $9.094M $6.813M
YoY Change 151.83% 129.53% 47.6%
SHAREHOLDERS EQUITY
Retained Earnings -$97.76M -$84.73M
YoY Change -0.04% 88.46%
Common Stock $3.000K $3.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $124.2M $135.3M $147.2M
YoY Change
Total Liabilities & Shareholders Equity $133.6M $144.4M $154.0M
YoY Change -22.01% 51.5% 178.92%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$12.31M -$13.04M -$10.61M
YoY Change 33.59% 80.75% 69.71%
Depreciation, Depletion And Amortization $22.00K $19.00K $17.00K
YoY Change 120.0% 90.0% 70.0%
Cash From Operating Activities -$11.96M -$8.999M -$10.02M
YoY Change 23.25% 4.77% 85.23%
INVESTING ACTIVITIES
Capital Expenditures -$24.00K $44.00K -$90.00K
YoY Change 300.0% 76.0% -1000.0%
Acquisitions
YoY Change
Other Investing Activities $9.107M $5.471M $8.243M
YoY Change -133.74%
Cash From Investing Activities $9.083M $5.427M $8.153M
YoY Change -133.65% -21808.0% -81630.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $6.000K
YoY Change -96.79%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 43.00K 6.000K 119.0K
YoY Change -99.95% -99.99% -99.75%
NET CHANGE
Cash From Operating Activities -11.96M -8.999M -10.02M
Cash From Investing Activities 9.083M 5.427M 8.153M
Cash From Financing Activities 43.00K 6.000K 119.0K
Net Change In Cash -2.830M -3.566M -1.749M
YoY Change -105.76% -109.48% -104.19%
FREE CASH FLOW
Cash From Operating Activities -$11.96M -$8.999M -$10.02M
Capital Expenditures -$24.00K $44.00K -$90.00K
Free Cash Flow -$11.93M -$9.043M -$9.931M
YoY Change 23.07% 4.98% 83.23%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001637715
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24458290
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2070935
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24458550
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.48
CY2021Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.2235
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
139000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4542202
CY2022Q1 dei Entity File Number
EntityFileNumber
001-40315
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Reneo Pharmaceuticals, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2309515
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
18575 Jamboree Road, Suite 275-S
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92612
CY2022Q1 dei City Area Code
CityAreaCode
858
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
283-0280
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
RPHM
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24458550
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
121094000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
124660000
CY2022Q1 us-gaap Short Term Investments
ShortTermInvestments
17568000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
23010000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4053000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6064000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
142715000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
153734000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
237000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
212000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1382000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
78000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
78000
CY2022Q1 us-gaap Assets
Assets
144412000
CY2021Q4 us-gaap Assets
Assets
154024000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1566000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2022000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5887000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4180000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
457000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7910000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6202000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1127000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
167000
CY2022Q1 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
57000
CY2021Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
444000
CY2022Q1 us-gaap Liabilities
Liabilities
9094000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2070935
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
147211000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-42115000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
471000
CY2021Q4 us-gaap Liabilities
Liabilities
6813000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24458550
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24457838
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24455390
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
233015000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
231902000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-97764000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-84728000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
64000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
34000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
135318000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
147211000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
144412000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
154024000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9278000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5472000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3737000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1742000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
13015000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
7214000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13015000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7214000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-21000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-13036000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7212000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
30000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13006000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7212000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.48
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24458290
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1107000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
30000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-13036000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
135318000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7212000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-48717000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-13036000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7212000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1107000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
471000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1000
CY2022Q1 rphm Fair Value Changes Of Share Based Performance Award
FairValueChangesOfShareBasedPerformanceAward
-387000
CY2022Q1 rphm Operating Lease Right Of Use Asset Amortization Expense Lease Modification And Impairment
OperatingLeaseRightOfUseAssetAmortizationExpenseLeaseModificationAndImpairment
-143000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1251000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-927000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2011000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
929000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-108000
CY2021Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8999000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8589000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
44000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
16029000
CY2022Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
21500000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5427000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
187000
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1223000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46222000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3566000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
37608000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
124660000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53613000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
121094000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
91221000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1524000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2000
CY2021Q1 rphm Unpaid Convertible Preferred Stock Issuance Costs
UnpaidConvertiblePreferredStockIssuanceCosts
19000
CY2021Q1 rphm Initial Public Offering Costs Incurred But Not Yet Paid
InitialPublicOfferingCostsIncurredButNotYetPaid
361000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19021269
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
444000
CY2021Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On April 5, 2021, the Company effected a 1-for-4.4748 reverse stock split of its common stock. The par value and the authorized number of shares of the common stock were not adjusted as a result of the reverse stock split. The reverse stock split resulted in an adjustment to the Series A and Series B convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented.
CY2021Q1 rphm Cash And Cash Equivalents At Carrying Value And Short Term Investments
CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments
138700000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-97800000
CY2022Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2022Q1 rphm Changed In Fair Value Of Share Based Performance Award
ChangedInFairValueOfShareBasedPerformanceAward
-387000
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
57000
CY2022Q1 rphm Accrued Clinical And Regulatory Expenses
AccruedClinicalAndRegulatoryExpenses
2049000
CY2021Q4 rphm Accrued Clinical And Regulatory Expenses
AccruedClinicalAndRegulatoryExpenses
1236000
CY2022Q1 rphm Accrued Development Expenses
AccruedDevelopmentExpenses
2176000
CY2021Q4 rphm Accrued Development Expenses
AccruedDevelopmentExpenses
1482000
CY2022Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1218000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1027000
CY2022Q1 rphm Accrued Other Research And Development Expenses
AccruedOtherResearchAndDevelopmentExpenses
444000
CY2021Q4 rphm Accrued Other Research And Development Expenses
AccruedOtherResearchAndDevelopmentExpenses
435000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5887000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4180000
CY2022Q1 us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
true
CY2022Q1 us-gaap Lease Practical Expedient Use Of Hindsight
LeasePracticalExpedientUseOfHindsight
true
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.05
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.49
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
399000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
414000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
323000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
332000
CY2022Q1 rphm Lessee Operating Lease Liability To Be Paid After Year Three
LesseeOperatingLeaseLiabilityToBePaidAfterYearThree
285000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1753000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
169000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1584000
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7286601
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4215643
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
233600
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.80
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
713
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.45
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
185828
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.48
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4262702
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.52
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
379000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
1490020
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.20
CY2022Q1 rphm Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
P6Y4M24D
CY2022Q1 rphm Share Based Compensation Arrangement By Share Based Payment Award Options Vested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue
368000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2703228
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.49
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
375000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
10400000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.018
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.007
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.852
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.712
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1107000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
471000

Files In Submission

Name View Source Status
0001558370-22-008103-index-headers.html Edgar Link pending
0001558370-22-008103-index.html Edgar Link pending
0001558370-22-008103.txt Edgar Link pending
0001558370-22-008103-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rphm-20220331.xsd Edgar Link pending
rphm-20220331x10q.htm Edgar Link pending
rphm-20220331x10q004.jpg Edgar Link pending
rphm-20220331x10q_htm.xml Edgar Link completed
rphm-20220331xex31d1.htm Edgar Link pending
rphm-20220331xex31d2.htm Edgar Link pending
rphm-20220331xex32d1.htm Edgar Link pending
rphm-20220331xex32d2.htm Edgar Link pending
rphm-20220331_cal.xml Edgar Link unprocessable
rphm-20220331_def.xml Edgar Link unprocessable
rphm-20220331_lab.xml Edgar Link unprocessable
rphm-20220331_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending